Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126603122 | 12660312 | 2 | F | 201201 | 20160916 | 20160817 | 20160922 | EXP | US-ASTRAZENECA-2010BM06379 | ASTRAZENECA | 642.00 | MON | F | Y | 120.20000 | KG | 20160922 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126603122 | 12660312 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | A678711A | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | ||||||
| 126603122 | 12660312 | 2 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | FT0082 | 0 | 2 | MG | /wk | |||||||
| 126603122 | 12660312 | 3 | C | EXENATIDE | EXENATIDE | 1 | 0 | SOLUTION FOR INJECTION | |||||||||||
| 126603122 | 12660312 | 4 | C | GLUCOPHAGE | METFORMIN HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126603122 | 12660312 | 5 | C | TUMS | CALCIUM CARBONATE | 1 | 0 | ||||||||||||
| 126603122 | 12660312 | 6 | C | NEURONTIN | GABAPENTIN | 1 | Oral | POSSIBLE 200MG, TWICE A DAY | 0 | ||||||||||
| 126603122 | 12660312 | 7 | C | NEURONTIN | GABAPENTIN | 1 | Oral | POSSIBLE 200MG, TWICE A DAY | 0 | ||||||||||
| 126603122 | 12660312 | 8 | C | NOVOLOG | INSULIN ASPART | 1 | Subcutaneous | 7 UNITS OVER 450 | 0 | ||||||||||
| 126603122 | 12660312 | 9 | C | LEVEMIR | INSULIN DETEMIR | 1 | Subcutaneous | 46 UNITS IN THE AM AND 40 UNITS IN THE PM | 0 | ||||||||||
| 126603122 | 12660312 | 10 | C | VITAMINS | VITAMINS | 1 | 0 | ||||||||||||
| 126603122 | 12660312 | 11 | C | INSULIN | INSULIN NOS | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126603122 | 12660312 | 1 | Type 2 diabetes mellitus |
| 126603122 | 12660312 | 2 | Type 2 diabetes mellitus |
| 126603122 | 12660312 | 5 | Nausea |
| 126603122 | 12660312 | 6 | Neuropathy peripheral |
| 126603122 | 12660312 | 7 | Pain |
| 126603122 | 12660312 | 8 | Type 2 diabetes mellitus |
| 126603122 | 12660312 | 9 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126603122 | 12660312 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126603122 | 12660312 | Abdominal mass | |
| 126603122 | 12660312 | Glycosylated haemoglobin increased | |
| 126603122 | 12660312 | Intentional product misuse | |
| 126603122 | 12660312 | Localised infection | |
| 126603122 | 12660312 | Lymphoedema | |
| 126603122 | 12660312 | Nausea | |
| 126603122 | 12660312 | Needle issue | |
| 126603122 | 12660312 | Neuropathy peripheral | |
| 126603122 | 12660312 | Pain in extremity | |
| 126603122 | 12660312 | Peripheral swelling | |
| 126603122 | 12660312 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126603122 | 12660312 | 1 | 20100428 | 0 | ||
| 126603122 | 12660312 | 6 | 2016 | 0 | ||
| 126603122 | 12660312 | 7 | 2016 | 0 |